GILEAD SCIENCES, INC. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Gilead reported Q3 2026 product sales of $8.3B (+13% YoY), with product sales excluding Veklury at $8.2B (+16%). HIV sales grew 18% to $6.2B, driven by Biktarvy ($4.1B, +10%) and Descovy ($1.0B, +49%). The company raised full-year 2026 product sales guidance to $31.0–$31.3B (previously $30.1–$30.4B), representing a cumulative $1.6B increase since January 2026. However, GAAP diluted EPS fell to $1.94 (from $2.43 YoY) due to equity losses and higher operating expenses; non-GAAP diluted EPS rose to $2.55 (from $2.47). Cash declined to $6.4B from $10.6B, reflecting $11.3B in acquisition outflows (Arcellx, Tubulis, Ouro, PepStar), $2.8B debt repayment, $3.1B dividends, offset by $11.2B operating cash flow.
Why this rating
Guidance raise and strong core HIV growth are meaningful but modest relative to $103B market cap (~1.6% uplift). Acquisitions and IPR&D charges ($9.88/share) create near-term EPS drag; cash burn material but manageable.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.